Mozart Therapeutics

Mozart Therapeutics

  • Founded: 2020
  • Location: Seattle, WA
  • Employee range: 11 - 50
  • Clinical stage: Clin0
  • Therapy area: Autoimmune GI disorders
  • Drug types: IMM, GI
  • Lead product: Undisclosed
  • Product link:
  • Funding: $25M A Jun 2023; $55M A Oct 2021
  • Investors: Pfizer Ventures, AbbVie Ventures, Ono Venture Investment, UPMC Enterprises, ARCH Venture Partners, Sofinnova Partners, Eli Lilly & Company, MRL Ventures Fund, Leaps by Bayer, Altitude Life Science Ventures, Alexandria Venture Investments

job board

Short description:

CD8 Treg cell modulators

Drug notes:

2 additional undisclosed programs RD/Clin0 undisclosed

Long description:

Mozart Therapeutics is a Seattle-based biopharmaceutical company focused on developing disease-modifying therapies for autoimmune and inflammatory diseases. They aim to modulate the immune system, specifically focusing on a specific subset of CD8 T cells. Their approach utilizes regulatory CD8 T cell modulators, molecules designed to target and activate these specific regulatory CD8 T cells. These cells play a critical role in self-tolerance, and a defective regulatory network leads to tissue destruction. Activation of regulatory CD8 T cells is intended to restore immune balance and prevent the excessive inflammatory response seen in autoimmune diseases, therefore halting, or preventing tissue damage. Some of their programs target autoimmune-mediated gastrointestinal disease.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy